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Qa-1b and its human homologue human leu-
kocyte antigen (HLA)-E are conserved MHC 
class  I  like  molecules,  often  categorized  as 
“nonclassical” or class Ib MHC. Similar to the 
classical MHC molecules, they accommodate 
small  peptides  in  their  binding  grooves  and 
present these on the cell surface (Jensen et al., 
2004; Rodgers and Cook, 2005). Crystal struc-
tures of HLA-E show that the overall fold of 
the peptide–MHC complex is very similar to 
that  of  the  classical  MHC  class  I  molecules 
(O’Callaghan et al., 1998). The unique feature 
of Qa-1b and HLA-E resides in the very lim-
ited  number  of  alleles  that  is  present  in  the 
population (Grimsley et al., 2002; Hermel et al., 
2004): as few as two alleles exist in the human 
population, differing in just one amino acid;   
this difference has hardly any functional conse-
quence (Strong et al., 2003). The monomor-
phic nature of Qa-1b and HLA-E is underlined 
by  the  finding  that  they  are  predominantly 
filled with one peptide ligand, which is derived 
from the signal sequence of classical MHC class 
I molecules, often referred to as Qa-1 deter-
minant modifier (Qdm; Aldrich et al., 1994; 
DeCloux et al., 1997). These signal peptides 
are strikingly conserved in all tested mamma-
lian species (Kurepa et al., 1998), pointing at 
an important function of this peptide–MHC 
combination for the immune system. A sub-
stantial body of evidence reveals that it regu-
lates NK cells and CTLs via the heterodimeric 
receptors CD94/NKG2A and CD94/NKG2C 
(Braud et al., 1998a; Vance et al., 1999; Rodgers   
and  Cook,  2005).  These  germline-encoded 
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The nonclassical major histocompatibility complex (MHC) Qa-1b accommodates monomor-
phic leader peptides and functions as a ligand for germ line receptors CD94/NKG2, which 
are expressed by natural killer cells and CD8+ T cells. We here describe that the conserved 
peptides are replaced by a novel peptide repertoire of surprising diversity as a result of 
impairments in the antigen-processing pathway. This novel peptide repertoire represents 
immunogenic neoantigens for CD8+ T cells, as we found that these Qa-1b–restricted T cells 
dominantly participated in the response to tumors with processing deficiencies. A surpris-
ingly wide spectrum of target cells, irrespective of transformation status, MHC background, 
or type of processing deficiency, was recognized by this T cell subset, complying with the 
conserved nature of Qa-1b. Target cell recognition depended on T cell receptor and Qa-1b 
interaction, and immunization with identified peptide epitopes demonstrated in vivo prim-
ing of CD8+ T cells. Our data reveal that Qa-1b, and most likely its human homologue 
human leukocyte antigen-E, is important for the defense against processing-deficient cells 
by displacing the monomorphic leader peptides, which relieves the inhibition through CD94/
NKG2A on lymphocytes, and by presenting a novel repertoire of immunogenic peptides, 
which recruits a subset of cytotoxic CD8+ T cells.
© 2010 Oliveira et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
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Here, we describe the existence of a surprisingly broad 
peptide repertoire that is presented by Qa-1b on cells with 
impairments  in  the  antigen-processing  machinery.  These 
peptides replace Qdm and are targeted by a unique popula-
tion of CD8+ cytotoxic T cells. Normal cells with intact   
processing machinery were not recognized by these Qa-1b–
restricted  CTL,  but  partial  defects  readily  resulted  in  the   
appearance  of  the  immunogenic  self  peptides,  which  are   
derived from housekeeping proteins. Interestingly, we show 
that these Qa-1b–restricted T cells are abundantly present in 
the immune response to processing deficient tumors. Our 
data show that the nonclassical Qa-1b molecule plays a prom-
inent role in the adaptive immune response as a restriction 
element for T cells and presents a much larger peptide reper-
toire than thus far anticipated.
RESULTS
Qa-1b–restricted T cells are frequently present  
in the immune response against TAP-deficient tumors
We previously described that the immune response against 
TAP-deficient  tumors  comprises  Qa-1b–restricted  T  cells 
among T cells with MHC restriction to the classical class I 
molecules (van Hall et al., 2006). This prompted us to deter-
mine the relative contribution of this Qa-1b–restricted subset 
to the overall response. Mice were immunized with syngeneic 
TAP-deficient  RMA-S  cells  expressing  the  co-stimulatory 
molecule CD80. Ex vivo–cultured spleens were examined for 
IFN- production against the parental RMA-S lymphoma, 
the 2m-negative C4.4-25 line, and a panel of single class I–
expressing EC7.1 cells, which are MHC class I–loss variants of 
RMA-S (Howell et al., 2000; Table I). All polyclonal ex vivo 
cultures responded to RMA-S, but not against the 2m-
negative  lymphoma,  indicating  that  they  exhibited  specific   
T cell reactivity against TAP-deficient tumors, and not merely 
reflected natural killer (NK) cell reactivity. Dissection of these 
IFN- responses revealed a codominance of Qa-1b–restricted 
activity compared with those restricted by the classical Db- and 
Kb-molecules, as the majority of the examined 12 independent 
cultures  produced  high  IFN-  levels  when  incubated  with 
EC7.1.Qa-1b (Table I). These data suggested that the nonclassical   
receptors specifically engage the Qdm peptide when bound 
to Qa-1b/HLA-E because residues at peptide position 5 and 
8 are part of the surface interface of the CD94/NKG2 recep-
tors (Kaiser et al., 2008; Petrie et al., 2008). Interestingly, this 
interaction is quite similar to the footprint of the hyper vari-
able regions of the T cell receptor on peptide–MHC class I 
(Rudolph and Wilson, 2002). Absence of these Qdm side 
chain residues results in lack of receptor engagement (Valés-
Gómez et al., 1999; Miller et al., 2003), indicating that this 
innate receptor is truly peptide specific. Qdm–Qa-1b com-
plexes act as remote sensors of integrity of the MHC class I 
antigen-processing machinery, because defects in proteasomal 
cleavage, TAP-mediated peptide transport, signal peptidases 
or tapasin-mediated peptide loading all result in failure to 
process and present Qdm peptides (Braud et al., 1998b; 
Lemberg et al., 2001; Bland et al., 2003; Li et al., 2004). The 
lack of Qdm–Qa-1b complexes at the cell surface is sensed by 
NK cells expressing CD94/NKG2 receptors, and allows for 
immunosurveillance  of  such  processing-deficient  cells  (Lu   
et al., 2006). Thus, this receptor/ligand system is a major 
molecular mechanism behind the “missing self” principle of 
NK cell reactivity (Ljunggren and Kärre, 1990).
In addition to their role in the innate immune system, Qa-1b 
and HLA-E serve the adaptive response as well. T cell receptor 
recognition of these nonclassical MHCs has been described in 
the context of immunity against intracellular pathogens, e.g., 
Listeria, Salmonella, and Mycobacterium tuberculosis (Seaman et al., 
1999; Lo et al., 2000; Heinzel et al., 2002), suggesting that for-
eign antigens can replace the “self” Qdm peptides and be recog-
nized by CD8+ T cells. HLA-E–restricted T cells specific for the 
human Qdm homologue do exist, but have only been reported 
in response to allogeneic MHC (García et al., 2002; Romagnani 
et al., 2002). Furthermore, Qa-1b–restricted CD8+ T cells have 
been implicated in the regulation of experimental autoimmune 
diseases (for review see Jiang and Chess, 2000; Lu et al., 2006). 
The antigenic targets of these regulatory T cells are most likely 
of self origin, but different from Qdm. These data reveal that 
Qa-1b/HLA-E–restricted T cells are present in the host, but that 
the specificity, diversity, and function of this T cell subset await 
further investigation.
Table I.  Detection of Qa-1b–directed IFN- responses in ex vivo cultures
Target cellsa           Independent T cell cultureb      
  1 2 3 4 5 6 7 8 9 10 11 12
RMA-S 5,723c 10,113 1,204 6,582 12,199 4,896 2,894 10,389 1,359 11,593 4,320 1,567
C4.4-25 97 84 92 82 164 61 23 18 106 61 47 14
EC7.1 364 712 310 216 1,311 799 273 81 485 564 418 38
EC7.1.Kb 5,886 11,270 538 7,184 16,031 2,526 441 8,309 405 11,111 1,552 837
EC7.1.Db 888 7,507 645 690 10,113 2,125 1,129 604 648 8,314 1,561 446
EC7.1.Qa-1b 2,053 5,579 3,330 6,677 16,265 3,108 2,999 272 1,410 8,827 2,697 7,039
EC7.1.cont 380 700 386 250 1,370 1,065 418 63 591 620 401 56
Medium 287 120 287 152 276 156 177 38 218 110 74 13
aRMA-S is TAP2 deficient; C4.4-25 is 2m deficient; EC7.1 is a MHC class I–deficient variant of RMA-S. Single class I genes were reconstituted in EC7.1.
b12 mice were immunized with RMA-S.B7 and spleens were stimulated twice in vitro with RMA-S.B7 before testing.
cConcentration of IFN- released by ex vivo cultures (pg/ml).JEM VOL. 207, January 18, 2010 
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tantly,  NK  lineage  markers  NK1.1  and  DX5,  and  CD16, 
CD32, and CD244 (2B4) were not expressed. Neither were 
receptors of the lectin Ly49 family, which interact with classi-
cal MHC class I (Fig. S1 and not depicted). We concluded that 
our Qa-1b–restricted T cells are indistinguishable at the pheno-
typic level from conventional CD8+ T cells restricted by classi-
cal MHC (McMahon and Raulet, 2001), but are clearly distinct 
from  the  reported  Qa-1–recognizing  intestinal  +  T  cells 
(Davies et al., 2004) and Qa-1–restricted regulatory CD8+ 
T cell subset (Tang et al., 2006).
To carefully determine the Qa-1b restriction of our iso-
lated T cell clones, we examined their reactivity against two 
cell panels, based on the TAP-negative EC7.1 lymphoma 
and TAP-deficient B78H1 melanoma (Fig. 1; Howell et al., 
2000; Chiang et al., 2003). Both cell lines are also devoid of 
MHC class I proteins and single class I molecules were recon-
stituted by gene transfer. All isolated T cell clones exhibited 
cytolytic activity (Fig. 1 A) and produced IFN- (Fig. 1 B 
MHC class I Qa-1b frequently acts as an antigen presentation 
molecule for T cells, and can even overrule the classical MHC 
class I molecules.
Critical involvement of Qa-1b and the T cell receptor  
in target cell recognition
To characterize these Qa-1b–restricted T cells, we isolated sev-
eral T cell clones from the aforementioned cultures and exten-
sively explored the expression and function of surface receptors. 
All clones displayed a classical CTL phenotype and expressed 
CD3, CD8, and TCR (Fig. S1). Different rearranged 
TCR V segments were used (unpublished data), validating 
the independent origin of the clones and indicating that Qa-1b 
recognition does not constrain the TCR repertoire. In addi-
tion to the T cell lineage receptors, the T cell clones also ex-
pressed CD94, NKG2A, NKG2C, and NKG2D, receptors 
that are frequently found on NK cells, which interact with 
nonclassical MHC class I molecules, including Qa-1b. Impor-
Figure 1.  Selective recognition of Qa-1b-expressing target cells. Isolated T cell clones were tested against panels of TAP-deficient lymphoma 
(EC7.1) and melanoma (B78H1) cells. Both cell lines are also deficient in MHC class I (Howell et al., 2000; Chiang et al., 2003) and were reconstituted with 
constructs encoding H-2Db, -Kb, or Qa-1b. Cytotoxic activity against Qa-1b–expressing EC7.1 cells (A) and IFN- production against Qa-1b-expressing 
B78H1 cells (B) by three independent T cell clones. Control Qdm-specific CTL failed to recognize the Qa-1b expressing targets because of the absence of 
TAP, unless pulsed with the Qdm peptide (right). Means and standard deviations of triplicate wells are shown for one out of three comparable 
experiments.210 CD8+ T cell repertoire restricted by Qa-1b | Oliveira et al.
H-2Db and Kb knockout mice. Qdm peptides are derived 
from the leader sequence of H-2Db (Aldrich et al., 1994), 
and loss of this allele resulted in recognition by two of the 
and  Fig.  S2)  against  the  Qa-1b–expressing  cells,  but  not 
against cells in which only Db or Kb were introduced. These 
data convincingly demonstrated the Qa-1b restriction of our 
T cells and excluded cross-reactivity to the classical class I 
molecules. Qdm-specific control CTL did not recognize the 
TAP-deficient tumor targets, as the presentation of Qdm in 
Qa-1b is TAP dependent (Aldrich et al., 1994). Exogenous   
loading of Qdm conferred reactivity for this CTL clone   
(Fig. 1, right). A direct interaction with Qa-1b was revealed 
by the finding that anti–Qa-1b antibody strongly blocked the 
recognition by our CTL (Fig. 2 A).
Next, we examined the involvement of antigen-receptors 
in target cell recognition. Although CD94/NKG2A and 
CD94/NKG2C  do  engage  Qa-1b  (Rodgers  and  Cook, 
2005) and were expressed by our isolated T cell clones, 
their  involvement  was  not  likely,  because  TAP-negative 
cells are devoid of peptide ligands for these receptors (Gays   
et  al.,  2001).  Indeed,  blocking  with  NKG2A/C-specific   
antibodies did not alter the response, whereas anti-CD3   
and -CD8 antibodies clearly inhibited the recognition of 
EC7.1.Qa-1b cells (Fig. 2 B). A role for NKG2D was also 
not  likely,  as  our  RMA-based  lymphoma  panel  lacks 
NKG2D ligands (Diefenbach et al., 2000). Together, these 
data indicated that the TCR governed the reactivity of our 
Qa-1b–restricted CTL.
Furthermore, exogenous loading with excessive amounts 
of competing Qdm peptides inhibited T cell recognition of 
EC7.1.Qa-1b cells (Fig. 2 C). Similar competition was found 
when the Qdm variant L8K was used (AMAPRTLKL), but 
not with irrelevant control peptide (Fig. 2 C, left). Qdm-
specific control CTL confirmed that both peptides are effi-
ciently loaded on the target cells (Fig. 2 C, right). The fact 
that the position 8 substitution in the peptide L8K prevents 
engagement to CD94/NKG2A receptors (Kraft et al., 2000), 
but retained the capacity to inhibit T cell reactivity in our   
assays, substantiated our findings that target cell recognition is 
regulated by TCR-mediated interaction with Qa-1b and not 
by NK receptors.
TAP- and MHC heavy chain deficiencies are targeted  
by Qa-1b–restricted CTL
To evaluate the appearance of the peptide epitopes on target 
cells that express natural levels of Qa-1b, we tested B cell 
blasts from spleens of wild-type, TAP1-deficient, and 2m-
deficient mice as targets for three independently derived CTL 
clones (Fig. 3 A). TAP1-deficient cells were efficiently rec-
ognized by all three clones, but wild-type and 2m-deficient 
cells  were  not.  Qdm-specific  control  CTL  selectively  re-
sponded to wild-type cells, indicating that the absence of 
Qdm peptides caused by the TAP defect promoted the pre-
sentation of the new peptide epitopes. Qa-1b surface levels 
on TAP1-deficient cells were lower than on wild-type cells, 
but were clearly higher than the background levels on 2m-
deficient cells (unpublished data).
We also analyzed CTL reactivity against MHC class I 
heavy chain deficiencies with the use of B cell blasts from 
Figure 2.  The T cell receptor, but not NKG2A/C, mediates reactiv-
ity of the T cells. (A) Blocking antibody against Qa-1b demonstrated a 
direct role of this molecule for T cell recognition. Experiment was per-
formed using EC7.1.Qa-1b target cells and repeated three times with simi-
lar outcome. (B) Blocking CD3 or CD8 with monoclonal antibodies 
decreased T cell reactivity against TAP-deficient EC7.1.Qa-1b target cells. 
Antibodies against NKG2A/C did not alter the T cell response, indicating 
that only the T cell receptor is critically involved in mediating reactivity. 
Data are representative of four experiments. (C) Exogenous peptide load-
ing competes with endogenously presented epitopes on EC7.1.Qa-1b cells 
and inhibits the recognition of these target cells by Qa-1b–restricted CTL 
(left). Qdm (AMAPRTLLL) or Qdm L8K (AMAPRTLKL) peptides were loaded 
exogenously at the indicated concentrations on EC7.1.Qa-1b cells and 
IFN- release by CTL was measured. Control peptide was the Kb-binding 
8-mer SIINFEKL from OVA. The Qdm L8K mutant peptide–Qa-1b complexes 
fail to interact with CD94/NKG2A or CD94/NKG2C (Kraft et al., 2000), 
indicating that the loaded peptides interfere with T cell receptor–mediated 
reactivity. Qdm-specific control CTL (right) was activated by the peptides. 
Means and standard deviations of triplicate wells are shown for one out 
of three comparable experiments.JEM VOL. 207, January 18, 2010 
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CTL reactivity against tumors with partial  
processing impairments
We then determined CTL reactivity against tumor cells with 
TAP dysfunction and tumor cells with undefined deficiencies 
in the processing machinery. Ad5-transformed mouse em-
bryo cells (Ad5MEC) and chemically induced fibrosarcoma 
cells (methylcholantrene [MCA]), both derived from TAP1-
knockout  mice,  were  recognized  by  the  Qa-1b–restricted 
CTL (Fig. 4 A). Correction of the TAP1 defect by gene 
transfer resulted in decreased recognition by our CTL and 
strongly increased recognition by the Qdm-specific control 
CTL (Fig. 4 A). Thus, the alternative Qa-1b–binding peptide 
antigens are expressed in a wide array of hematopoietic and 
nonhematopoietic tissues of normal and transformed cells, 
including B cells, fibroblasts, lymphoma, melanoma, and sar-
coma, and emerge at the cell surface of cells with genetic dis-
ruption of the TAP peptide transporter.
However, human tumors mostly display partial deficien-
cies in their processing pathway that originate at the tran-
scriptional  level,  resulting  in  an  impairment,  but  not  a 
complete shutdown, in the generation of the human coun-
terpart  of  Qdm–Qa-1b  complexes.  To  assess  whether  the 
CTL were also capable of recognizing such tumor cells, we 
three CTL clones, whereas deficiency in Kb heavy chains 
did not result in recognition (Fig. 3 B). These subtle differ-
ences between the CTL clones suggested that the cognate 
peptides are differentially influenced by loss of MHC class I 
heavy chains. Strikingly, all three CTL clones strongly re-
sponded to cells devoid of both alleles (H-2DbKb knockout; 
Fig. 3 B). Control blasts lacking 2m and H-2DbKb (triple 
knockout) were not recognized. These results revealed an 
unexpected influence of the Kb molecule on the Qa-1b–
presented antigenic peptides, in that removal of Kb mole-
cules from H-2Db–deficient cells strongly enhanced epitope 
display (Fig. 3 B). The underlying mechanism of this effect 
is currently elusive. The degree of CTL response to H-
2DbKb  knockout  cells  was  comparable  to  TAP-deficient 
cells (Fig. 3 A), indicating that both defects led to optimal 
presentation  of  the  new  Qa-1b  peptides.  Interestingly, 
Qdm-specific CTL were able to differentiate between these 
two target populations, confirming previous findings that 
this CTL clone is also reactive to TAP-dependent peptides 
other than Qdm (Cotterill et al., 1997; Gays et al., 2001). 
Together,  these  results  demonstrated  that  our  Qa-1b–
  restricted CTL interact with peptides on activated B cells 
with defects in the antigen presentation route.
Figure 3.  Qa-1b–restricted CTL are reactive against cells with defined processing deficiencies. (A) LPS-stimulated B cell blasts from wild-type 
(B6), TAP1/, and 2m/ mice were used as targets for Qa-1b–restricted CTL (left) or control Qdm-specific CTL (right). (B) LPS-stimulated B cell blasts 
from wild-type (B6), MHC class I knockout, and MHC class I/2m knockout mice were tested for recognition by Qa-1b–restricted CTL (left) or control 
Qdm-specific CTL (right). Graphs display representative experiments out of four performed. Means and standard deviations of triplicates are shown.212 CD8+ T cell repertoire restricted by Qa-1b | Oliveira et al.
Determination of the Qa-1b–presented peptide repertoire
We set out to determine the nature of the TAP-independent 
peptides that are presented by Qa-1b via biochemical purifica-
tion and tandem mass spectrometry (MS). Because of the lack 
of suitable Qa-1b–specific antibodies, we made use of a chime-
ric MHC class I molecule in which the peptide binding do-
mains ( 1 and 2) of Qa-1b were coupled to the constant  3 
domain of Db, against which good precipitating antibodies are 
available. This chimeric Qa-1b/Db molecule was introduced 
into TAP2-negative EC7.1 cells and to compare the corre-
sponding TAP-dependent peptide repertoire, we also created 
a TAP2-reconstituted variant of EC7.1.Qa-1b/Db cells. Flow 
cytometry data confirmed that EC7.1.Qa-1b/Db cells only ex-
pressed this chimeric molecule on the cell surface and not the 
endogenous Db molecule, excluding the risk that we would 
purify Db-binding peptides with our  3–directed antibody 
(Fig. 5 A). Analysis of TAP2 expression in EC7.1.Qa-1b/Db 
and in the TAP-transfected variant confirmed the absence of 
TAP2 protein in the first and successful reconstitution in the 
other (Fig. 5 B). Analysis with our Qa-1b–restricted CTL and 
Qdm-specific CTL confirmed that our EC7.1 cell lines repre-
sented two extremes of the antigen-processing status, in that 
the TAP-negative line did not present Qdm and that reconsti-
tution of TAP2 led to a disappearance of the newly defined 
tested four chemically induced mouse colon carcinomas, which 
are known to possess peptide presentation capacity (Rodolfo   
et al., 1994; Yang and Perry-Lalley, 2000). Qdm-specific con-
trol CTL, indeed, recognized all four cell lines, demonstrating 
functional processing machinery (Fig. 4 B, right). Interestingly, 
our Qa-1b–restricted CTL responded to all carcinoma lines, 
albeit to varying extents (Fig. 4 B, left). Treatment of the car-
cinomas with the immunostimulatory cytokine IFN-, which 
strongly improves the processing and presentation capacity of 
cells, resulted in decreased recognition, pointing at partial pro-
cessing defects in the carcinomas that were corrected by IFN-. 
In line with this idea, gene transfer of the viral TAP inhibitor 
UL49.5 (van Hall et al., 2007) led to a strongly increased rec-
ognition by our CTL. As expected, the Qdm-specific control 
CTL clone exhibited the opposite reactivity profile (Fig. 4 B, 
right). Of note, the four colon carcinoma lines were derived 
from two mouse strains with different MHC typing, BALB/c 
with H-2d alleles (C26 and CC36) and C57BL/6 with H-2b 
alleles (MC38 and CMT93), nicely illustrating the conserved 
nature of Qa-1, which is the same in these strains.
We concluded that our Qa-1b–restricted CTL recognize 
peptide epitopes that even appear on the surface of cells with 
mild or partial processing impairments, implying that a mixture 
of Qdm and TAP-independent peptides can coexist in Qa-1b.
Figure 4.  Partial deficiencies in the processing pathway of tumor cells induce the novel Qa-1b–presented peptide-epitopes. (A) Qa-1b–
  restricted CTL respond to Ad5-transformed mouse cells (Ad5MEC) and fibrosarcoma cells (MCA) that are derived from TAP1 knockout mice. Recognition 
was lost upon gene transfer of mouse TAP1 in these cell lines (+ TAP1). Qdm-specific control CTL displayed opposing specificity, indicating that the Qdm  
peptide is only presented on TAP-proficient tumor cells (right). (B) Four colon carcinoma cell lines from BALB/c (C26 and CC36) or C57BL/6 (MC38 and 
CMT93) background were used as targets for both CTL types. Pretreatment with IFN- to boost the antigen-processing and presentation machinery  
resulted in decreased reactivity by the Qa-1b–restricted CTL, whereas gene transfer of the viral TAP-inhibitor UL49.5 (van Hall et al., 2007) led to strongly 
increased recognition. Again, Qdm-specific control CTL displayed opposing specificity (right). Means and standard deviations of triplicates are shown  
from one representative experiment out of four.JEM VOL. 207, January 18, 2010 
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database (http://www.ebi.ac.uk/IPI/IPImouse.html) and 
analysis of their corresponding synthetic peptides confirmed 
the amino acid sequence of 84 peptides. The other peptide 
masses could not be matched with a known peptide sequence, 
but did not correspond to Qdm or previously defined Qa-
1b–binding peptides (Rodgers and Cook, 2005). The lengths 
of the TAP-independent peptides ranged from 8 to 18 amino 
acids, but the majority were 9 amino acids long (Fig. 5 D). 
Seven peptides were found in length variants (Table II, num-
bers 65 to 84), and six of these families varied at their C ter-
minus, reminiscent of leader peptide processing (Martoglio 
and Dobbertein, 1998). However, only one of these families 
was actually encoded in the leader domain, suggesting that 
peptides and that the chimeric molecule functionally presented 
Qa-1b–bound peptides (Fig. 5 C).
MS  of  peptide  species  from  purified  Qa-1b  molecules 
demonstrated an evident difference between the two peptide 
repertoires. The peptide repertoire of TAP-positive cells was 
strikingly  dominated  by  the  Qdm  peptide  AMAPRTLLL 
(Table II). Six other peptide sequences were identified, but 
these represented only minor constituents (together <5% of 
the total ion count). In contrast, Qa-1b from TAP-negative 
cells was filled with a remarkable diversity of peptides from 
endogenous proteins (Table II). No peptide clearly stood out 
in terms of quantity. More than 150 tandem mass fragmenta-
tion profiles sufficiently matched with the mouse IPI protein 
Figure 5.  Identification of the TAP-independent peptide repertoire of Qa-1b. (A) The chimeric Qa-1b/Db class I molecule was expressed in EC7.1 
cells, which are TAP- and MHC class I–negative. TAP-positive counterparts were generated by introduction of the TAP2 gene. Surface display on EC7.1.Qa-
1b/Db cells of the chimeric molecule and absence of the endogenous Db molecule was determined by flow cytometry with Qa-1b– and Db3-specific anti-
bodies and Db2-specific antibody, respectively, as indicated in the histogram plots (clone KH95 and also H131-31; not depicted). Staining of 
TAP-reconstituted cells gave comparable results. Control TAP-proficient RMA cells displayed endogenous Qa-1b and Db molecules. (B) TAP expression was 
analyzed on RMA, RMA-S, EC7.1, and EC7.1.TAP2 cells by Western blot using the antibody TAP2.688 against mouse TAP2. Results confirmed the lack of 
TAP2 expression on EC7.1 and RMA-S cells. (C) The chimeric construct was recognized by CTL clones: the TAP-negative variant only by Qa-1b–restricted 
CTL (black bars) and the TAP-positive variant only by Qdm-specific CTL (gray bars). Means and standard deviations of triplicate wells are shown from one 
representative experiment out of four. (D) Peptide purification and MS analysis revealed the wide diversity of the TAP-negative peptide repertoire, whereas 
the TAP-positive peptide repertoire was mainly limited to the Qdm peptide. Data were collected from four independent experiments in the case of TAP-
negative repertoire and two independent experiments for TAP-positive repertoire. Number of different peptides with indicated length is depicted of 84 
identified peptides that are listed in Table II.214 CD8+ T cell repertoire restricted by Qa-1b | Oliveira et al.
Table II.  List of Qa-1b-binding peptides isolated from TAP-positive and TAP-negative tumor cells
Peptide number Peptide sequence Peptide 
location




  1 AMAPRTLLL 3-11 362 P01899 H-2 class I histocompatibility antigen, D-B alpha chain
  2 AQAERTPEL 691-699 1274 A2RT67 DENN domain-containing protein 3
  3 IINTHTLLL 1302-1310 1657 Q80UW7 IQ motif containing GTPase activating protein 1
  4 PKFEVIDKPQS 98-108 108 P97450 ATP synthase-coupling factor 6, mitochondrial
  5 PTEEESPV 486-493 493 P53986 Monocarboxylate transporter 1
  6 QAIPQGAIQ 246-254 461 Q8BG99 Homeobox protein PKNOX2
  7 QLQPQQPLPQPQ 125-136 672 Q9WVH4 Forkhead protein FKHR2
TAP-negative
  1 AAIENIEHL 1193-1201 1392 Q6PB66 Leucine-rich PPR motif-containing  
protein, mitochondrial
  2 AALKLGQEL 799-807 1271 Q9JJ28 Protein flightless-1 homologue
  3 AAPTNANSLNSTF 454-466 575 Q8BT14 CCR4-NOT transcription complex subunit 4
  4 AAPTSPDHSPA 699-709 709 Q66L44 Protein Dos
  5 AAVIAHDFL 153-161 292 P30282 G1/S-specific cyclin-D3
  6 AGIENDEAF 44-52 248 B1AWD9 Clathrin light polypeptide
  7 AGPENSSKI 383-346 2075 Q80XK6 Autophagy-related protein 2 homologue B
  8 AGQFNQDYL 45-53 503 Q921F1 Annexin A11
  9 AGVRNPQQHL 515-524 636 Q8BN32 Pabpc1 protein
  10 ASLQNFNISNL 2103-2113 2128 B2RRJ7 Wnk1 protein
  11 KSISNPPGSNL 2115-2125 2128 B2RRJ7 Wnk1 protein
  12 ASQQNSEEM 202-210 210 Q9CXE2 B-cell CLL/lymphoma 7 protein family member A
  13 ASVLNVNHI 2195-2203 2603 Q99NH0 Ankyrin repeat domain-containing protein 17
  14 ASYRAQPSVSL 270-280 573 Q62019 16 kD protein
  15 ATPGRLIDFL 256-265 648 Q5U222 Ddx5 protein
  16 AVSEGTKAVTKYTSAK 111-126 126 Q8CGP1 Histone H2B type 1-K
  17 FAPLPRLPTL 17-26 156 Q9CR21 Acyl carrier protein, mitochondrial
  18 FAPVNVTTEVKSVE 280-293 462 P10126 Elongation factor 1-alpha 1
  19 FAYEGRDYI 137-145 184 Q62143 Qa-2 cell surface antigen
  20 FGPVNHEEL 33-41 147 P46414 Cyclin-dependent kinase inhibitor 1B
  21 FQIVNPHLL 634-642 792 Q6NZB3 Ribonucleoside-diphosphate reductase
  22 FQVTHTVAL 113-121 361 Q9QYA2 Mitochondrial import receptor subunit TOM40 
homologue
  23 GGPINPATA 1036-1044 1107 Q80X50 Ubiquitin-associated protein 2-like
  24 GLGVLLAF 5-12 113 Q8QZT4 Crumbs protein homologue 3
  25 HSIQNSQDM 61-69 210 Q91YN9 BAG family molecular chaperone regulator 2
  26 IQKTPQIQVY 21-30 119 P01887 Beta-2-microglobulin
  27 KAPPPLPPLVVF 27-38 499 P16277 Tyrosine-protein kinase BLK
  28 KAPTNEFYA 190-198 198 O35988 Syndecan-4
  29 KCSVSIQVVDVNDNYPEL 328-345 794 Q91XZ8 Protocadherin beta 22
  30 KSAVGHEYV 96-107 486 Q922I8 Hematopoietic cell specific Lyn substrate 1
  31 LAIRNDEEL 93-101 137 Q64426 Histone H2A
  32 LVRPGTALEL 2294-2303 2883 NP_076331 desmoplakin
  33 METLTATPQ 976-984 1241 B2RXW8 Ppfia1 protein
  34 NSIRNLDTI 100-108 475 P28658 Ataxin-10
  35 PADIVKNLK 12-20 341 Q8VDZ8 Calcium binding protein 39
  36 PDTGISSKA 52-60 126 Q8CGP2 Histone H2B type 1-P
  37 PEAFPALA 385-392 392 Q9CY58 Plasminogen activator inhibitor 1 RNA-binding protein
  38 PNKLVELNK 138-146 943 Q6DFV7 Nuclear receptor coactivator 7JEM VOL. 207, January 18, 2010 
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Peptide number Peptide sequence Peptide 
location
Protein length UniProtKB or 
SwissProt number
Protein description
  39 PPSAKAAID 97-105 323 Q5SSG6 TATA box binding protein (TBP)-associated factor
  40 PPTAKAAVE 425-433 661 Q5SUS9 Ewing sarcoma breakpoint region 1
  41 PVKAVEIEI 155-163 930 Q7TSZ1 Xeroderma pigmentosum, complementation group C
  42 RSPENPPSKEL 171-181 181 Q9CQA0 Centromere protein M
  43 RSPGNSPTPM 186-195 469 Q8CI61 BAG family molecular chaperone regulator 4
  44 SALINLSSF 7-15 161 Q8VE65 Transcription initiation factor TFIID subunit 12
  45 SAPENAVRM 28-36 126 O35127 Protein C10
  46 SAPSNFEHR 12-20 593 Q8BTW9 Serine/threonine-protein kinase PAK 4
  47 SAPTGSGKTL 227-236 639 Q6P9R1 ATP-dependent RNA helicase DDX51
  48 SAVISLEGKPL 156-166 166 P18760 Cofilin-1
  49 SAVSNNYIQTL 168-178 911 P30999 Catenin delta-1
  50 SHRKFSAPR 2-10 403 Q3U9L3 ribosomal protein L3P family member
  51 SLGINPHVL 966-974 1170 B2RQL0 Nup98 protein
  52 SLGKNPTDAYL 60-70 172 Q3THE2 Myosin regulatory light chain MRLC2
  53 SQPESKVFYL 110-119 245 P63101 Protein kinase C inhibitor protein 1
  54 SSTTNPKLSTL 726-736 959 Q5NBZ5 Eukaryotic translation initiation factor 4E nuclear 
import factor 1
  55 STIRLLTSL 458-466 545 P80318 T-complex protein 1 subunit gamma
  56 TNPESKVFYL 155-160 284 P68254 14-3-3 protein theta
  57 TQGQNIQHL 431-439 2326 Q80YT7 Myomegalin
  58 VAVTNGPRS 371-379 393 Q9D6J1 LAG1 longevity assurance homologue 4
  59 VPPVQVSPLIKFGRY 2-16 71 Q5EBI8 ATP synthase, H+ transporting, mitochondrial  
F1F0 complex
  60 VQVSNFKSGKGDSTL 254-268 579 Q80WJ7 Metastasis adhesion protein
  61 VSLLDIDHL 473-481 679 Q8BQM4 HEAT repeat-containing protein 3
  62 VSLLNPPETL 411-420 422 Q8BRG1 Cyclin A2, isoform CRA
  63 VTLVNHGSTF 15-24 640 P59110 SUMO-1 protease 2
  64 YGYSNRVVDLM 316-326 333 P16858 Glyceraldehyde-3-phosphate dehydrogenase
 
  65 AAPRSGPSV 611-619 641 Q923D5 WW domain-binding protein 11
  66 AAPRSGPSVA 611-620 641 Q923D5 WW domain-binding protein 11
  67 AGIENKFGL 648-656 676 Q9QXX4 Calcium-binding mitochondrial carrier protein Aralar2
  68 AGIENKFGLYL 648-658 676 Q9QXX4 Calcium-binding mitochondrial carrier protein Aralar2
  69 AGIENKFGLYLP 648-659 676 Q9QXX4 Calcium-binding mitochondrial carrier protein Aralar2
  70 TKAVTKYTSSK 117-127 127 A0JNS9 Histone H2B
  71 GTKAVTKYTSSK 116-127 127 A0JNS9 Histone H2B
  72 SEGTKAVTKYTSSK 114-127 127 A0JNS9 Histone H2B
  73 VSEGTKAVTKYTSSK 113-127 127 A0JNS9 Histone H2B
  74 AVSEGTKAVTKYTSSK 112-127 127 A0JNS9 Histone H2B
  75 PEPAKSAPAPK 2-12 126 Q64478 Histone H2B type 1-H
  76 PEPAKSAPAPKKG 2-14 126 Q64478 Histone H2B type 1-H
  77 LGVKNSEPA 59-67 576 Q80UG5 Septin-9
  78 LGVKNSEPAA 59-68 576 Q80UG5 Septin-9
  79 SSPANISSLEFEDA 583-596 773 P51125 Calpastatin
  80 SSPANISSLEFEDAK 583-597 773 P51125 Calpastatin
  81 SSPANISSLEFEDAKLS 583-599 773 P51125 Calpastatin
  82 SSPANISSLEFEDAKLSA 583-600 773 P51125 Calpastatin
  83 KPLFEILNG 1138-1146 1735 Q9IZU3 Endogenous mouse mammary tumor virus Mtv1
  84 KPLFEILNGD 1138-1147 1735 Q9IZU3 Endogenous mouse mammary tumor virus Mtv1
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amino acid trimming at the C terminus might be a feature of 
TAP-independent peptides in general. Strikingly, no clear 
binding motif could be elucidated in our peptide repertoire, 
although  previous  studies  with  synthetic  peptide  libraries 
showed a dominant role for position 2 (M or L; Kraft et al., 
2000). The C terminus of the peptides frequently contained 
an aliphatic amino acid (L, I, M, A, and F; Table II), as found 
for most mouse MHC class I alleles.
We concluded that the presence of the high-affinity bind-
ing peptide Qdm in the groove of Qa-1b prevents the ac-
commodation  and  display  of  a  broad  array  of  alternative 
peptides and that this new repertoire only emerges upon pro-
cessing defects.
Immunogenicity of the Qa-1b-binding peptides
A direct consequence of the absence of this alternative pep-
tide repertoire under physiological conditions is that this rep-
ertoire may comprise neoantigens for the CD8+ T cell system. 
To estimate the immunogenicity of the identified Qa-1b–
binding peptides, we tested them in a matrix-based screening 
approach in which each peptide was systematically repre-
sented in two different peptide pools containing five peptides 
each. None of our Qa-1b–restricted T cell clones recognized 
peptides  from  the  identified  repertoire,  so  polyclonal  re-
sponder T cells from mice immunized with TAP-deficient 
EC7.1.Qa-1b.B7 tumors were applied, assuring that the pep-
tide-directed responses were induced by naturally presented 
antigens. Responses of 25 independent T cell cultures were 
compiled and final immunogenicity scores revealed several 
immunogenic peptides (Fig. 6 A). These peptide antigens 
had no common amino acid motif and were derived from 
different housekeeping proteins (see corresponding numbers   
in Table II), again pointing at the broad diversity of this anti-
gen repertoire. To assess the potency of the five most immuno-
genic peptide sequences (number 3, 12, 17, 29, and 41) to 
induce CD8+ T cell responses in vivo, we immunized mice 
with the peptides in conjunction with imiquimod as adju-
vant. After two vaccinations, clear populations of peptide-
specific CD8+ T cells were detectable in the blood (Fig. 6, 
B–D). The peptides with the largest T cell populations also 
scored high in the immunogenicity screen in which tumor-
stimulated T cells were applied (Fig. 6 A). Interestingly, pep-
tide immunizations in H-2Db/Kb/ mice did not lead to 
Figure 6.  Immunogenicity of Qa-1b–presented peptides in vitro 
and in vivo. (A) Immunogenicity of 59 peptides was determined by com-
piling the IFN- response of 25e T cell cultures, which were induced by 
immunization with irradiated TAP-negative EC7.1.Qa-1b.B7 cells. Re-
sponses were measured using a matrix-based approach in which each 
peptide was represented in two independent pools. T cell responses 
against each pool were scored from zero to three and compiled scores 
from the two pools were multiplied. (B–D) Percentage of IFN-–producing 
CD8+ T cells in the blood of mice that were naive (B) or immunized with 
the indicated peptide (C). Blood samples were taken and cells were stimu-
lated overnight with medium or specific peptide, stained with antibodies, 
and analyzed by flow cytometry. Collected data from peptide-specific 
frequencies of CD8+ cells from mice are depicted in (D). Each data point 
represents one mouse, and data from two independent experiments is 
shown. (E–G) Cytotoxic reactivity in vivo in the same mice as shown in D. 
Specific killing was determined in naive (E) or immunized mice (F) by 
comparing the numbers of CFSEhigh targets, which were loaded with rel-
evant peptides, to CFSElow targets, which were not loaded with peptide. 
CFSEintermediate targets were loaded with Qdm and were always comparable 
to targets without peptide. The means of percentage in vivo killing is de-
picted with standard deviations (G).
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housekeeping proteins and only emerge in Qa-1b on the cell 
surface when the processing pathway is hampered. We dem-
onstrated the display of these peptides in cells with partial and 
mild deficiencies that do not completely prevent Qdm from 
appearance, but a complete block in the processing pathway,   
e.g., loss of TAP1 or TAP2, resulted in the most efficient   
presentation of the novel peptides, demonstrating that TAP-
independent processing mechanisms are responsible for the 
replacement of Qdm. Surprisingly, cell surface expression of 
Qa-1b is less affected by TAP deficiency than classical MHC 
class I molecules (Kambayashi et al., 2004), and HLA-E 
surface expression has also been described in the absence of 
functional TAP proteins or class I–derived signal peptides   
(Furukawa et al., 1999; Palmisano et al., 2005). Qa-1b and 
HLA-E, indeed, seem to efficiently egress from the ER in the   
absence of TAP (Robinson et al., 1998; LoMonaco et al., 2008). 
These data implicate that our mouse studies are relevant for 
the human setting. Two alternative processing routes have 
been described by which peptides can bypass the TAP trans-
porter: N-terminal signal peptides, which are processed by 
signal peptide cleaving enzymes (Martoglio and Dobbertein, 
1998) and C-terminal ends of ER-resident proteins, can also 
be loaded without TAP function, although the responsible 
proteolytic enzymes have not been identified for this pathway 
(Snyder et al., 1998). 40% of the 84 identified peptides in our 
search were indeed located at the N or C terminus. Interest-
ingly, one of the most immunogenic Qa-1b peptide epitopes 
FAPLPRLPTL is encoded in the N-terminal signal sequence 
of a mitochondrial carrier protein (UniProt Q9CR21). The 
fact that 60% of the peptides cannot be explained by these two 
processing mechanisms suggests the existence of other yet   
uncharacterized processing pathways for MHC class I antigen 
presentation. It has been proposed that autophagy might   
contribute  to  MHC  class  I–restricted  antigen  presentation 
(Vyas et al., 2008). Autophagy is a crucial cellular mechanism   
responsible for the clearance of old or damaged cellular   
components, including organelles and macromolecules. This 
pathway might lead to the generation of peptides susceptible 
for MHC class I loading. Previous characterizations of pep-
tides bound to classical MHC class I from TAP-deficient   
cells revealed similar features: predominance of signal pep-
tides,  increased  peptide  lengths,  and  selective  presentation   
on  TAP-negative  variants  (Suri  et  al.,  2006;  Weinzierl   
et al., 2008). The Qa-1b peptide repertoires present on 
TAP-positive versus TAP-negative cells were extremely dif-
ferent (Table II), in that the high-affinity binding monomor-
phic Qdm strongly dominated the TAP-positive pool for   
>95%, whereas a broad diversity of other peptides was present 
in the TAP-negative pool. Previous comparisons of peptide 
repertoires  presented  by  classical  MHC  class  I  molecules 
showed much more overlap between the TAP-positive and   
-negative pools (Suri et al., 2006; Weinzierl et al., 2008). This 
indicates that the high-affinity binding Qdm competes with 
the TAP-independent peptides, and thereby prevents their 
presentation  under  normal  circumstances.  However,  even 
mild or partial processing deficiencies in tumor cells already 
a population of IFN-–positive CD8+ T cells, indicating that 
the T cell repertoire in these knockout mice is tolerant for 
the novel Qa-1b binding peptides (Fig. S3). This is in line 
with the finding that H-2Db/Kb/ target cells efficiently   
presented these peptides (Fig. 3 B), which are part of the nor-
mal Qa-1b peptide repertoire inducing central tolerance in 
these mice. Importantly, the vaccine-induced CD8+ T cells 
in wild-type mice exhibited strong cytolytic reactivity in vivo 
against target cells that were loaded with the relevant peptide 
(Fig. 6, E–G). Unloaded target cells and cells loaded with 
Qdm peptide were not killed in vivo. Vaccination with the 
Qdm peptide did not trigger any T cell immunity, illustrating 
that the T cell repertoire for this sequence does not exist or is 
functionally tolerant.
In conclusion, a broad repertoire of Qa-1b–binding peptide-
epitopes of self origin emerges at the surface of cells with   
impairments in the antigen-processing pathway and that this 
novel repertoire replaces the TAP-dependent Qdm. These 
results underscore a role of Qa-1b in adaptive immunity and 
infer that T cell responses are evoked via this nonclassical 
MHC molecule to prevent outgrowth of processing-deficient 
cells in the body.
DISCUSSION
The nonclassical MHC class I molecule Qa-1b normally pres-
ents monomorphic Qdm peptides derived from the leader 
sequences of classical MHC. This Qdm peptide–MHC com-
plex functions as a remote sensor of the class I processing 
pathway integrity through detection by CD94/NKG2A re-
ceptors on NK cells. Failure to present Qdm, caused by im-
pairments in proteolysis, TAP, or other means, increases the 
susceptibility of cells to attack by these lymphocytes. We 
show that Qdm under such conditions is replaced by a sur-
prisingly broad repertoire of alternative self-peptides. This 
novel peptide repertoire comprises neoantigens for which the 
T cell system is not hampered by immunological tolerance 
and can therefore induce a vigorous response of Qa-1b–
  restricted CD8+ CTL. This antigen presenting function of 
Qa-1b places this conserved MHC molecule at the intersection 
of innate and adaptive immunity. On one hand, it plays a role 
as a monomorphic inhibiting ligand when Qdm is presented, 
and, on the other hand, as a display system of an immunogenic 
self-peptide repertoire. Our data suggest that the immune 
system is equipped with multiple mechanisms to remove 
processing-deficient cells from the body.
The finding that Qa-1b is capable of presenting other pep-
tides than Qdm is supported by previous work from several 
groups. The leader of the CMV protein UL40 was found   
to be presented, as well as peptides from Salmonella, Listeria,   
Epstein-Barr virus, and Mycobacterium tuberculosis (Rodgers and 
Cook, 2005). Furthermore, an increase of Hsp60 in the cellu-
lar  stress  response  was  shown  to  result  in  replacement  of   
the human Qdm homologue with the Hsp60 signal peptide 
(Michaëlsson et al., 2002). The unique feature, however, of 
the peptide repertoire we have elucidated in our current work 
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deficient variant of EL4. RMA-S.B7-1 is a CD80 transfectant of RMA-S. 
EC7.1 is a Kb- and Db-negative variant of RMA-S (Howell et al., 2000). B78H1 
is a TAP-deficient and MHC class I–deficient melanoma (Chiang et al., 2003). 
Tap1/ and wild-type mouse embryo fibroblasts were immortalized by the 
adenovirus type 5 E1 gene (Ad5MEC, clone XC3). Tap1/ fibrosarcoma 
was induced with MCA (clone MCB6TAP). Gene transfer of mouse TAP1, 
mouse TAP2, H-2Db, H-2Kb, and Qa-1b (T23 gene) was performed with ret-
roviruses based on the MuLV vector LZRS. Generation of CTL clones was 
performed according to previous description (van Hall et al., 2006). In brief, 
syngeneic C57BL/6 mice were immunized with irradiated RMA-S.B7-1 cells 
and in vitro stimulated weekly with a mixture of RMA-S.B7-1 and EC7.1.Qa-
1b.B7-1 cells, naive splenocytes, and IL-2. Qa-1b–restricted CTL clone B12i 
that is reactive with the TAP-dependent AMAPRTLLL peptide was isolated 
from a B6.Tla mouse (Cotterill et al., 1997).
All mice were purchased from Iffa-Credo and housed in the animal facil-
ity of the Leiden University Medical Center under specific pathogen–free 
conditions and used between 8 and 12 wk of age. TAP1-knockout mice were 
purchased  from  Jackson  ImmunoResearch  Laboratories  and  MHC  class  I 
knockout animals were obtained from F. Lemonnier (Institut Pasteur, Paris, 
France; Pérarnau et al., 1999). Experiments were performed in accordance 
with Dutch national legislation and institutional guidelines and were approved 
by the animal ethical committee of the Leiden University Medical Center.
CTL assays and flow cytometry. CTL activity was measured by chro-
mium (51Cr) release assay or IFN- ELISA as previously described (van Hall   
et al., 2000). Data shown represent mean values obtained from triplicate test-
wells, and the error bars represent standard deviation of these values. For anti-
body blocking, CTL were pretreated with 20 µg/ml antibodies, washed, and 
added as responders to target cells for IFN- release. The following antibodies 
were used in functional blocking assays: hamster anti-CD3 (Fab2 fragments of 
clone 145-2C11), control hamster anti-TNP, rat anti-CD4 (clone GK1.4), rat 
anti-CD8 (clone 2.43) anti-NKG2A/C (clone 20d5), and anti-Qa-1b (clone 
6A8.6F10.1A6). For flow cytometry analysis, the following monoclonal anti-
bodies were purchased from BD: Ly49AB6 (clone A1), Ly49C/I (clone 5E6), 
Ly49G  (clone  LGL-1),  Qa-1b  (clone  6A8.6F10.1A6),  NKG2AB6  (clone 
16a11), CD94 (clone 18d3), CD3 (clone 145-2C11), CD8 (clone Ly2), 
CD8 (clone Ly-3.2.), CD4 (clone GK1.4), CD16/CD32 (clone 2.4G2), 
NK1.1 (clone PK136), CD49b (clone DX5), and CD244 (clone 2B4). From 
eBioscience we purchased NKG2D (clone CX5).
Peptide elution, HPLC, and MS. Peptides were eluted out of purified 
chimeric Qa-1b/Db molecules from EC7.1 cells. The genomic H-2Db con-
struct in which the  1 and  2 domains were exchanged with those of   
Qa-1b was provided by P.J. Dyson (Imperial College, Hammersmith Hospital, 
London, UK; Cotterill et al., 1997). This genomic construct was expressed 
in HeLa cells, and cDNA was then cloned into the retroviral construct 
LZRS. EC7.1 cells transduced with this construct were twice sorted by 
FACS. TAP-positive counterparts were generated by retroviral gene transfer 
of the mouse TAP2 gene. Immunoprecipitation of Qa-1b/Db molecules was 
performed with protein A beads covalently coupled with anti-Db mAb 28–
14-8S from two and four independent lysates of 40.109 TAP-positive and 
TAP-negative EC7.1 cells, respectively, as previously described (van Hall   
et al., 2000). The peptide pools were prefractionated on a C18 RP-HPLC 
system (200 µm × 15 cm; Reprosil-C18-AQ 3 µm; Dr. Maisch GmbH). 
Fractions were reduced to near dryness, diluted in 95/3/0.1 vol/vol/vol 
water/acetonitril/formic acid and subsequently analyzed by tandem MS. 
Peptides were analyzed by nanoflow liquid chromatography using an Agilent 
1100 HPLC system (Agilent Technologies), as previously described (van 
Hall et al., 2006), and coupled on line to a 7-tesla LTQ-FT mass spectrome-
ter (Thermo Electron). The end of the nanocolumn was drawn to a tip (in-
ternal dimaeter [ID] 5 µm), from which the eluent was sprayed into the 
mass spectrometer. Peptides were trapped at 5 µl/min on a 1-cm column 
(100-µm ID; ReproSil-Pur C18-AQ, 3 µm) and eluted to a 15 cm column 
(50-µm ID; ReproSil-Pur C18-AQ, 3 µm) at 150 nl/min in a 60-min gradi-
ent from 0 to 50% acetonitrile in 0.1% formic acid.
led to the presentation of both types of peptides, as illustrated 
by the fact that Qdm-specific CTL and our Qa-1b–restricted 
CTL were able to recognize the four colon tumors (Fig. 4). 
Importantly, Qdm is not immunogenic because of the wide-
spread  presentation  in  the  normal  host,  including  thymus 
(Sullivan et al., 2002), and thereby prevent tolerance mecha-
nisms for CTL specificities that recognize the new emerging 
peptide-epitopes. We indeed found that T cells specific for 
these novel Qa-1b–peptides are deleted in mice that do pres-
ent these peptides in Qa-1b molecules during T cell develop-
ment, as in H-2Db/Kb/ mice (Fig. S3).
Our Qa-1b–restricted T cells exhibit a normal phenotype 
for  CD8+  T  lymphocytes  (Fig.  S1)  and  use  rearranged 
TCRs, and thereby distinguish themselves from reported 
Qa-1–recognizing intestinal + T cells (Davies et al., 2004) 
and the Qa-1–restricted regulatory CD8+ T cell subset 
(Tang et al., 2006). Target cell recognition was mediated by 
the TCR and this receptor did not cross-react with classical 
class I molecules, indicating that also, at the functional level, 
this subset is not different from conventional CD8+ T lym-
phocytes. This is in line with data from mice lacking classical 
MHC class I molecules arguing that 10% of the total CD8+ 
T cell subset is restricted by nonclassical molecules (Pérarnau 
et al., 1999; Seaman et al., 1999; Ureta-Vidal et al., 1999; 
Vugmeyster et al., 1998). This T cell repertoire is heteroge-
neous, as witnessed by a diverse usage of TCRV segments 
(Pérarnau et al., 1999; Ureta-Vidal et al., 1999). Selection of 
Qa-1b–restricted T cells in the thymus, indeed, does occur 
(Sullivan et al., 2002), but it remains puzzling how a mono-
morphic Qdm–Qa-1b complex can mediate positive selec-
tion resulting in such a broad repertoire. Furthermore, the 
relationship between the suppressive Qa-1b–restricted T cells 
(Jiang and Chess, 2000; Lu et al., 2006) and the tumor-reactive 
T cells described here remains elusive.
We speculate that comparable T cell subsets exist in 
human beings, especially because Qa-1b and HLA-E are rather 
conserved  in  structure  and  function  (Rodgers  and  Cook, 
2005). TCR-mediated recognition of HLA-E has been pre-
viously described (García et al., 2002; Heinzel et al., 2002; 
Romagnani et al., 2002), and it is highly likely that a subset 
similar to our Qa-1b-CTL, which responds against tumors 
with processing impairments, is present in humans. HLA-E 
surface  expression  is  ubiquitous  in  the  body  and  even   
detected in the absence of the human Qdm homologue 
(Furukawa et al., 1999; Palmisano et al., 2005), although 
MHC class I leaders strongly stimulate HLA-E display (Braud 
et al., 1998b; Lee et al., 1998). The lack of polymorphism in 
the human population infers that identified neoantigens pre-
sented in HLA-E constitute universal epitopes that might   
be exploited for the therapy of frequently occurring tumor 
immune escape variants and persistent infections by viruses 
encoding immune evasion proteins.
MATERIALS AND METHODS
Cell lines and mice. The origin and culturing of most cell lines used in this 
study was described previously (van Hall et al., 2006). C4.4-25 is a 2m-JEM VOL. 207, January 18, 2010 
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positive control. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20091429/DC1.
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